Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Maravai LifeSciences Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Maravai LifeSciences Holdings, Inc.’s stock price such as:

• Maravai LifeSciences Holdings, Inc.’s current stock price and volume
• Why Maravai LifeSciences Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for MRVI from analysts
• MRVI’s stock price momentum as measured by its relative strength

About Maravai LifeSciences Holdings, Inc. (MRVI)

Before we jump into Maravai LifeSciences Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Want to learn more about Maravai LifeSciences Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Maravai LifeSciences Holdings, Inc..

Maravai LifeSciences Holdings, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Maravai LifeSciences Holdings, Inc.’s stock price was $6.570.

Maravai LifeSciences Holdings, Inc. is down 2.67% from its previous closing price of $6.750.

During the last market session, Maravai LifeSciences Holdings, Inc.’s stock traded between $6.450 and $6.770. Currently, there are approximately 146.43 million shares outstanding for Maravai LifeSciences Holdings, Inc..

Maravai LifeSciences Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Maravai LifeSciences Holdings, Inc. Stock Price History

Maravai LifeSciences Holdings, Inc.’s (MRVI) price is currently up 5.29% so far this month.

During the month of July, Maravai LifeSciences Holdings, Inc.’s stock price has reached a high of $7.440 and a low of $5.670.

Over the last year, Maravai LifeSciences Holdings, Inc. has hit prices as high as $7.440 and as low as $1.990. Year to date, Maravai LifeSciences Holdings, Inc.’s stock is up 102.15%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Maravai LifeSciences Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Maravai LifeSciences Holdings, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Maravai LifeSciences Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Maravai LifeSciences Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Maravai LifeSciences Holdings, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Maravai LifeSciences Holdings, Inc. (MRVI) by visiting AAII Stock Evaluator.

Relative Price Strength of Maravai LifeSciences Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Maravai LifeSciences Holdings, Inc. has a weighted four-quarter relative price strength of 35.17%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Maravai LifeSciences Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Maravai LifeSciences Holdings, Inc. Stock Price: Bottom Line

As of July 31, 2026, Maravai LifeSciences Holdings, Inc.’s stock price is $6.570, which is down 2.67% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Maravai LifeSciences Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.